Osteoporosis is characterized by reduction in the density and quality of bones that often result in broken bones in the wrist, hip, and spine. Various factors responsible for osteoporosis include, genetic factors, low intake of calcium, magnesium, and vitamin D, eating disorders such as anorexia, inactivity and immobility, and excessive alcohol intake. Increasing approvals and launches of novel osteoporosis drugs along with increasing prevalence of osteoporasis is expected to significantly drive the osteoporosis treatment market growth over forecast period.
Key features of the study:
- This report provides in-depth analysis of the Global and China Osteoporosis Drugs Market and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
- It profiles key players in the Global and China Osteoporosis Drugs Market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include, Merck & Co., Eli Lilly, Procter & Gamble, Enzo Biochem, Inc., Sanofi-Aventis, Novartis, Wyeth, Roche, GlaxoSmithKline, UCB, Amgen, BeiGene Co., Ltd., Bone Biologics, Teijin Pharma Limited, JHL Biotech Inc., Keros Therapeutics, and Taro Pharmaceuticals Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The Global and China Osteoporosis Drugs Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global and China Osteoporosis Drugs Market
Detailed Segmentation:
- Global and China Osteoporosis Drugs Market, By Drug Type:
- Bisphosphonates
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic Acid
- Others
- Calcitonin
- Hormone Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Rank Ligand (RANKL) Inhibitor
- Global and China Osteoporosis Drugs Market, By Route of Administration:
- Global and China Osteoporosis Drugs Market, By Distribution Channel:
- Hospitals Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Global and China Osteoporosis Drugs Market, By Region:
- North America
- By Drug Type:
- Bisphosphonates
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic Acid
- Others
- Calcitonin
- Hormone Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Rank Ligand (RANKL) Inhibitor
- By Route of Administration
- By Distribution Channel
- Hospitals Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country
- Latin America
- By Drug Type:
- Bisphosphonates
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic Acid
- Others
- Calcitonin
- Hormone Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Rank Ligand (RANKL) Inhibitor
- By Route of Administration
- By Distribution Channel
- Hospitals Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Type:
- Bisphosphonates
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic Acid
- Others
- Calcitonin
- Hormone Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Rank Ligand (RANKL) Inhibitor
- By Route of Administration
- By Distribution Channel
- Hospitals Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country
- U.K.
- Germany
- France
- Spain
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Type:
- Bisphosphonates
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic Acid
- Others
- Calcitonin
- Hormone Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Rank Ligand (RANKL) Inhibitor
- By Route of Administration
- By Distribution Channel
- Hospitals Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country
- Japan
- India
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- China
- By Drug Type:
- Bisphosphonates
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic Acid
- Others
- Calcitonin
- Hormone Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Rank Ligand (RANKL) Inhibitor
- By Route of Administration
- By Distribution Channel
- Hospitals Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Middle East
- By Drug Type:
- Bisphosphonates
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic Acid
- Others
- Calcitonin
- Hormone Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Rank Ligand (RANKL) Inhibitor
- By Route of Administration
- By Distribution Channel
- Hospitals Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- By Drug Type:
- Bisphosphonates
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic Acid
- Others
- Calcitonin
- Hormone Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Rank Ligand (RANKL) Inhibitor
- By Route of Administration
- By Distribution Channel
- Hospitals Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country
- North Africa
- Central Africa
- South Africa
- Company Profiles
- Merck & Co. *
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Eli Lilly
- Procter & Gamble
- Enzo Biochem, Inc.
- Sanofi-Aventis
- Novartis
- Wyeth
- Roche.
- GlaxoSmithKline
- UCB
- Amgen
- BeiGene Co., Ltd.
- Bone Biologics
- Teijin Pharma Limited
- JHL Biotech Inc.
- Keros Therapeutics
- Taro Pharmaceuticals Inc.
- “*” marked represents similar segmentation in other categories in the respective section.
